Drugs / Beriplex P/N
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00168077 | Sep 2005 → Nov 2006 | acquired coagulation factor deficiency | CSL Behring | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beriplex P/N | “OBJECTIVES. To determine the effectiveness and safety of emergency OAT reversal by a balanced pasteurized nanofiltered PCC (Beriplex P/N) containing coagulation factors II,...” PMID 18208533 ↗ Jan 2008 |
| Action | Restore | “Prompt and sustained increases in circulating coagulation factors and anticoagulant proteins were observed.” PMID 18208533 ↗ Jan 2008 |
| Modality | Protein / enzyme biologic | “balanced pasteurized nanofiltered PCC (Beriplex P/N) containing coagulation factors II, VII, IX, and X, and anticoagulant proteins C and S” PMID 18208533 ↗ Jan 2008 |